Prenetics is a publicly listed company tracked for investment-relevant business developments.
Public market undervalues Prenetics relative to its IM8 supplement subsidiary's hypergrowth (100M ARR in 11 months, 200M in 18) and $1B growth financing from General Catalyst, creating a private/public valuation disconnect.